|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.06 USD | -1.10% |
|
+7.88% | +40.13% |
| 23/07 | Celldex Therapeutics, Inc. - Special Call | |
| 23/07 | Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Bullish |
| Resistance | 39.93 | 39.93 | 39.11 |
| Spread/Res. | -4.68% | -4.68% | -2.68% |
| Spread/Supp. | +17.36% | +33.26% | +32.98% |
| Support | 32.43 | 28.56 | 28.62 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- CLDX Stock
- Charts Celldex Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
